[{"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://tcbiopharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Executive Vice President of Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lauren  Bor Ph.D.", "title": "Head of Commercial Development Division", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.8504, "open": 0.89, "dayLow": 0.8402, "dayHigh": 0.89, "regularMarketPreviousClose": 0.8504, "regularMarketOpen": 0.89, "regularMarketDayLow": 0.8402, "regularMarketDayHigh": 0.89, "beta": 0.082, "forwardPE": -0.18265218, "volume": 12292, "regularMarketVolume": 12292, "averageVolume": 947268, "averageVolume10days": 50600, "averageDailyVolume10Day": 50600, "bid": 0.8181, "ask": 0.8998, "bidSize": 100, "askSize": 100, "marketCap": 4154898, "fiftyTwoWeekLow": 0.721, "fiftyTwoWeekHigh": 196.0, "fiftyDayAverage": 1.07658, "twoHundredDayAverage": 16.319395, "currency": "USD", "enterpriseValue": 83845168, "floatShares": 98345818, "sharesOutstanding": 4945130, "sharesShort": 24873, "sharesShortPriorMonth": 131198, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.005, "heldPercentInsiders": 0.00022, "heldPercentInstitutions": 0.00664, "shortRatio": 0.12, "shortPercentOfFloat": 0.0050999997, "impliedSharesOutstanding": 3195130, "bookValue": 0.338, "priceToBook": 2.4857988, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8593896, "trailingEps": -19.48, "forwardEps": -4.6, "lastSplitFactor": "1:20", "lastSplitDate": 1702598400, "enterpriseToEbitda": -6.488, "52WeekChange": -0.99190754, "SandP52WeekChange": 0.24919295, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCBP", "underlyingSymbol": "TCBP", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "firstTradeDateEpochUtc": 1644589800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef544858-646b-3e8d-bcb0-2aed3539a593", "messageBoardId": "finmb_1681274131", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8402, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 980955, "totalCashPerShare": 0.01, "ebitda": -12923699, "totalDebt": 1728127, "quickRatio": 0.459, "currentRatio": 0.882, "debtToEquity": 159.939, "returnOnAssets": -1.08915, "returnOnEquity": -12.1748, "freeCashflow": -6853025, "operatingCashflow": -10042216, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-07-11"}]